@article {7064,
	title = {Carfilzomib for treating myeloma},
	journal = {Expert Opinion on Orphan Drugs},
	volume = {4},
	year = {2016},
	note = {Cited By :1Export Date: 18 February 2017References: Moreau, P., Richardson, P.G., Cavo, M., Proteasome inhibitors in multiple myeloma: 10 years later (2012) Blood, 120 (5), pp. 947-959. , Aug;Rajkumar, S.V., Richardson, P.G., Hideshima, T., Proteasome inhibition as a novel therapeutic target in human cancer (2005) J Clin Oncol, 23 (3), pp. 630-639. , Jan; 
Richardson, P.G., Barlogie, B., Berenson, J., A phase 2 study of bortezomib in relapsed, refractory myeloma (2003) N Engl J Med, 348 (26), pp. 2609-2617. , Jun; 
Kortuem, K.M., Stewart, A.K., Carfilzomib (2013) Blood, 121 (6), pp. 893-897. , Feb; 
Richardson, P.G., Briemberg, H., Jagannath, S., Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib (2006) J Clin Oncol, 24 (19), pp. 3113-3120. , Jul; 
Muchtar, E., Gertz, M.A., Magen, H., A practical review on carfilzomib in multiple myeloma (2016) Eur J Haematol, 96 (6), pp. 564-577. , Jun; 
Meng, L., Mohan, R., Kwok, B.H., Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity (1999) Proc Natl Acad Sci USA, 96 (18), pp. 10403-10408. , Aug; 
Adams, J., The proteasome: structure, function, and role in the cell (2003) Cancer Treat Rev, 29, pp. 3-9. , May; 
Ciechanover, A., The ubiquitin-proteasome proteolytic pathway (1994) Cell, 79 (1), pp. 13-21. , Oct; 
Obeng, E.A., Carlson, L.M., Gutman, D.M., Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells (2006) Blood, 107 (12), pp. 4907-4916. , Jun; 
Adams, J., The proteasome: a suitable antineoplastic target (2004) Nat Rev Cancer, 4 (5), pp. 349-360. , May; 
Kuhn, D.J., Chen, Q., Voorhees, P.M., Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma (2007) Blood, 110 (9), pp. 3281-3290. , Nov; 
Kuhn, D.J., Hunsucker, S.A., Chen, Q., Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors (2009) Blood, 113 (19), pp. 4667-4676. , May; 
Kuhn, D.J., Orlowski, R.Z., Bjorklund, C.C., Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs) (2011) Curr Cancer Drug Targets, 11 (3), pp. 285-295. , Mar; 
Ruckrich, T., Kraus, M., Gogel, J., Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells (2009) Leukemia, 23 (6), pp. 1098-1105. , Jun; 
Oerlemans, R., Franke, N.E., Assaraf, Y.G., Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein (2008) Blood, 112 (6), pp. 2489-2499. , Sep; 
Gutman, D., Morales, A.A., Boise, L.H., Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma (2009) Leukemia, 23 (11), pp. 2181-2183. , Nov; 
Accardi, F., Toscani, D., Bolzoni, M., Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling (2015) Biomed Res Int, 2015, p. 172458; 
Demo, S.D., Kirk, C.J., Aujay, M.A., Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome (2007) Cancer Res, 67 (13), pp. 6383-6391. , Jul; 
Wang, Z., Yang, J., Kirk, C., Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib (2013) Drug Metab Dispos, 41 (1), pp. 230-237. , Jan; 
Alsina, M., Trudel, S., Furman, R.R., A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma (2012) Clin Cancer Res, 18 (17), pp. 4830-4840. , Sep; 
Lee, S.J., Levitsky, K., Parlati, F., Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay (2016) Br J Haematol; 
Squifflet, P., Michiels, S., Siegel, D., Relationship between carfilzomib dose and efficacy outcomes in patients with relapsed and/or refractory multiple myeloma (2015) Clin Lymphoma Myeloma Leuk, 15 (11), pp. 680-686. , Nov; 
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372 (2), pp. 142-152. , Jan; 
Dimopoulos, M.A., Moreau, P., Palumbo, A., Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study (2016) Lancet Oncol, 17 (1), pp. 27-38. , Jan; 
O{\textquoteright}Connor, O.A., Stewart, A.K., Vallone, M., A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies (2009) Clin Cancer Res, 15 (22), pp. 7085-7091. , Nov; 
Siegel, D.S., Martin, T., Wang, M., A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma (2012) Blood, 120 (14), pp. 2817-2825. , Oct; 
Jagannath, S., Vij, R., Stewart, A.K., An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma (2012) Clin Lymphoma Myeloma Leuk, 12 (5), pp. 310-318. , Oct; 
Vij, R., Wang, M., Kaufman, J.L., An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma (2012) Blood, 119 (24), pp. 5661-5670. , Jun; 
Wang, M., Martin, T., Bensinger, W., Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma (2013) Blood, 122 (18), pp. 3122-3128. , Oct; 
Bringhen, S., Petrucci, M.T., Larocca, A., Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study (2014) Blood, 124 (1), pp. 63-69. , Jul; 
Moreau, P., Kolb, B., Attal, M., Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma (2015) Blood, 125 (20), pp. 3100-3104. , May; 
Mikhael, J.R., Reeder, C.B., Libby, E.N., Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma (2015) Br J Haematol, 169 (2), pp. 219-227. , Apr; 
Korde, N., Roschewski, M., Zingone, A., Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma (2015) JAMA Oncol, 1 (6), pp. 746-754. , Sep; 
Siegel, D., Martin, T., Nooka, A., Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies (2013) Haematologica, 98 (11), pp. 1753-1761. , Nov; 
Li, Y.F., Wang, X., The role of the proteasome in heart disease (2011) Biochim Biophys Acta, 1809 (2), pp. 141-149. , Feb; 
Enrico, O., Gabriele, B., Nadia, C., Unexpected cardiotoxicity in haematological bortezomib treated patients (2007) Br J Haematol, 138 (3), pp. 396-397. , Aug; 
Rosenthal, A., Luthi, J., Belohlavek, M., Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? (2016) Blood Cancer J, 6, p. e384; 
Atrash, S., Tullos, A., Panozzo, S., Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib (2015) Blood Cancer J, 5, p. e272; 
Berenson, J.R., Cartmell, A., Bessudo, A., CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma (2016) Blood, 127 (26), pp. 3360-3368. , Jun; 
Danhof, S., Schreder, M., Rasche, L., {\textquoteleft}Real-life{\textquoteright} experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors (2015) Eur J Haematol; 
Delforge, M., Blade, J., Dimopoulos, M.A., Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues (2010) Lancet Oncol, 11 (11), pp. 1086-1095. , Nov; 
Cai, X., Bhattacharyya, S., Plitt, A., Management of posterior reversible encephalopathy syndrome induced by carfilzomib in a patient with multiple myeloma (2016) J Clin Oncol, 34 (2), pp. e1-e5. , Jan; 
Palumbo, A., Gay, F., Cavallo, F., Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma (2015) J Clin Oncol, 33 (30), pp. 3459-3466. , Oct; 
Berenson, J.R., Hilger, J.D., Yellin, O., Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy (2014) Leukemia, 28 (7), pp. 1529-1536. , Jul; 
Muchtar, E., Gatt, M.E., Rouvio, O., Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study (2016) Br J Haematol, 172 (1), pp. 89-96. , Jan; 
Kumar, S.K., Lee, J.H., Lahuerta, J.J., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study (2012) Leukemia, 26 (1), pp. 149-157. , Jan
},
	month = {2016},
	pages = {989 - 999},
	abstract = {Introduction: Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its initial approval by the Food and Drug Administration in 2012, either as a single agent or in combination with other known anti-myeloma treatments. Based on its efficacy and safety profile in the relapsed/refractory setting, carfilzomib is currently evaluated in patients with de novo MM. Areas covered: Here, we will shed some light on the introduction of carfilzomib as an effective anti-myeloma treatment, presenting its mechanism of action, its response rates and adverse events, as well as a summary of all clinical trials evaluating current dosage and schedule of administration. We will follow the entire path of drug{\textquoteright}s development from the bench of preclinical studies to the market and bedside delivery. Revising the published evidence, we will try to answer all questions raised about the novel drug, expressing in parallel our site experience. Expert opinion: Carfilzomib, alone or in combination with other agents, is a welcome therapeutic option for MM patients with a well-defined toxicity profile. Results of ongoing trials are expected in order to update drug indications and maximize its therapeutic benefits in patients with refractory/relapse MM. {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {Carfilzomib, multiple myeloma, newly diagnosed, proteasome inhibitor, relapsed/refractory},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84981194084\&doi=10.1080\%2f21678707.2016.1215909\&partnerID=40\&md5=72f33606ceda4213037b769dd97c4530},
	author = {Ziogas, D.C. and Terpos, E. and Kastritis, E. and Dimopoulos, M.A.}
}
